Pay in 4 interest-free payments of $7.07 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Mitochondrial Dysfunction in Diabetic Cardiomyopathy: Effect of Mesenchymal Stem Cell with PPAR- Agonist or Exendin-4
The FDA includes a warning about medullary thyroid carcinoma and advises against use in individuals with a family history of the disease or a family history of MEN 2
The average weight loss with Wegovy injection was 14.9% (34.6 lb / 15.7 kg) from a starting weight of 232 lb (105 kg) after 68 weeks in the STEP 1 clinical trial (NCT03548935), compared with 2.4% (5.5 lb / 2.5 kg) with placebo
Identification of anoikis-related molecular patterns to define tumor microenvironment and predict immunotherapy response and prognosis in soft-tissue sarcoma
US$ 24.61
US$ 28.37
US$ 24.57
US$ 26.74
US$ 22.78
